22.9 F
New York
Sunday, January 24, 2021

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Finds Drug Approval in Europe 

Must read

American Battery Metals Corp (OTCMKTS:ABML) Hitting Key Milestones

Over the course of the past week, American Battery Metals Corp (OTCMKTS:ABML) has been in focus among investors after the company announced...

American Green Inc (OTCMKTS:ERBB) Stock Gains Momentum on Amazon News

One of the more interesting operators in the cannabis space in 2020 is American Green Inc (OTCMKTS:ERBB), and this week, the company...

DSG Global Inc (OTCMKTS:DSGT) Hits Multi-Month High On Sudden Optimism

DSG Global Inc (OTCMKTS:DSGT) has been in the news over the past week or so after the company placed large orders through...

AppYea Inc (OTCMKTS:APYP) Stock Gains Momentum on High Volume

Over the past couple of weeks, many stocks in the over-the-counter market have recorded considerable gains and one of the notable ones...

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is coming off a tough 2016, but the company is making up for it this summer with +180% gains off recent news. The company’s drug is struggling to get FDA approvals, but could see approval in Europe (mostly in the bag already – details below). AVEO is still continuing to work toward FDA approval, but Europe is a large market and traders are reacting.

The drug, tivozanib, is being licensed in Europe by EUSA Pharma Inc. Tivozanib is intended for advanced renal cell carcinoma, which is the most common type of kidney cancer and is anticipated to be one of the fastest growing cancers in the next decade. AVEO failed to receive Food and Drug Administration approval for tivozanib back in 2013. The company has an ongoing phase 3 trial in third-line renal cell carcinoma, which is expected to read out in the first quarter of 2018. European approval of tivozanib would “add significant resources to our balance sheet as we work toward the anticipated readout,” AVEO Chief Executive Michael Bailey said (full quote below), including a $4 million research and development reimbursement payment and up to $12 million in additional milestone payments from EUSA Pharma.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America (mentioned above), and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

Find out when $AVEO stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Michael Bailey, president and chief executive officer of AVEO gave this quote after the company’s good news: “A positive opinion from the CHMP is a critical step in our goal of obtaining regulatory approval of tivozanib as a treatment for RCC. Tivozanib’s unique tolerability profile together with the longest progression free survival reported in a Phase 3 first line RCC study, have the potential to fill an unmet patient need for better tolerated treatment in this disease. If the European Commission grants marketing approval for tivozanib, it would trigger a $4 million research and development reimbursement payment from EUSA, and AVEO will also be eligible for up to $12 million in additional milestones from EUSA based on member state reimbursement and regulatory approvals. These payments would add significant resources to our balance sheet as we work toward the anticipated readout of our U.S. pivotal trial in third-line RCC, the TIVO-3 trial, in the first quarter of 2018.”

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) still have a chance for tivozanib to be approved here, but the company will probably need more operating cash. The company’s stock price has dwindled from 2012-2013, but there is still value here since the drug is tackling a fast-moving cancer. AVEO is on our radar and we will be reading the tea leaves for important test results here in the States. For continuing coverage on shares of Aveo’s stock, as well as our other breakout stocks, sign up for our free newsletter today and get our next hot stock pick!

Latest article

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Attempts To Rebound On Bullish Note

While the remarkable rally in Bitcoin has led to breathless speculation about its long term price, the recent rally in Grayscale Ethereum...

Sunhydrogen Inc (OTCMKTS:HYSR) Continues to Trend Higher on High Demand

One of the sectors to have come into significant focus among investors in recent times is the hydrogen...

Artificial Intelligence Technology Solutions (OTCMKTS: AITX) Moves Up Quickly On Solid Volume

The artificial intelligence industry has grown at a remarkable pace over the past half a decade or so and over the coming...

Signal Advance Inc (OTCMKTS:SIGL) Makes a Big Move, Again.

Speculation and confusion can often lead to strange occurrences on the stock markets and that is what happened...

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...